However, treatment of PyMT mice with the chemotherapeutic agent, doxorubicin, increases protein levels of CCR2 ligands CCL2 and CCL12 in the tumor stromal area, and promotes the recruitment of CCR2+ monocytes into the mammary tumors (76). This evidence concerns the gene CCL2 and breast cancer.